SCHEMBL3150165

SCHEMBL3150165

C=CC(=O)N1CCc2ccc(OC)cc2CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RYR2 Q92736 1/20 0.58
ESR1 P03372 1/20 0.56
ESR2 Q92731 1/20 0.56
TET3 O43151 1/20 0.52
KMT2A Q03164 1/20 0.52
FBXL19 Q6PCT2 1/20 0.52
CXXC5 Q7LFL8 1/20 0.52
TET1 Q8NFU7 1/20 0.52
KDM2B Q8NHM5 1/20 0.52
CXXC4 Q9H2H0 1/20 0.52
KDM2A Q9Y2K7 1/20 0.52
DRD1 P21728 7/20 0.51
DRD5 P21918 7/20 0.51
DRD2 P14416 6/20 0.51
DRD3 P35462 6/20 0.51
ABHD6 Q9BV23 1/20 0.51
DRD4 P21917 4/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA7 P43166 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10351344 0.82 ESR1 (0.62) ESR1ESR2DRD1DRD5DRD2
SCHEMBL3157148 0.82 HRH3 (0.53) KMT2A
SCHEMBL24490162 0.79 RYR2 (0.52) RYR2ESR1ESR2TET3KMT2A
SCHEMBL12209611 0.78 MTNR1B (0.60) ESR1ESR2DRD1DRD5DRD2
SCHEMBL21392851 0.78 KMT2A (0.50) RYR2ESR1ESR2TET3KMT2A
SCHEMBL8653185 0.77 MTNR1B (0.77) RYR2TET3KMT2AFBXL19CXXC5
SCHEMBL2309023 0.77 ESR1 (0.85) ESR1ESR2DRD1DRD5DRD2
SCHEMBL29338289 0.77 ESR1 (0.56) ESR1ESR2KMT2ADRD1DRD5
SCHEMBL11457061 0.77 MTNR1B (0.64) ESR1ESR2DRD1DRD5DRD2
SCHEMBL8247399 0.77 ESR1 (0.63) ESR1ESR2KMT2ADRD1DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076325-B2 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-12-13 US disclosed
EP-2036892-B1 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2010-03-10 EP disclosed
WO-2009066041-A2 DERIVATIVES OF 1,2,4,5-TETRAHYDRO-3H-BENZAZEPINES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2009-05-28 WO disclosed
EP-2036892-A1 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2009-03-18 EP disclosed
US-20090069296-A1 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069296-A1 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them OXER1, NR1H3, OXSR1 RYR2 720/4885ESR1 403/4885ESR2 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.